COLLCollegium Pharmaceutical Inc
Earnings Recap
• Reported GAAP EPS of $0.54 up 38.46% YoY • Reported revenue of $205.45M up 12.92% YoY • Collegium Pharmaceutical's Board authorized a new share repurchase program in July 2025 for up to $150M of common stock through December 31, 2026, which will depend on cash balances and future capital requirements.
Bullish
Collegium Pharmaceutical expanded its portfolio into neuropsychiatry with the Jornay PM acquisition, maintains low abuse rates for Xtampza ER, and benefits from intellectual property protection for key products extending to 2036.
Bearish
Collegium Pharmaceutical faces significant risks from generic competition for Nucynta IR and ER, potential increased operating costs from opioid-specific taxes, and supply chain disruptions due to reliance on limited API suppliers.